Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
L
Löthberg, Frida
Gyros Protein Technologies
(
T1330-02-11
)
Oligonucleotide Dual Hybridization Assay Using Offline Pre-incubation followed by an Automated Microfluidic Method
Frida Löthberg
Favorite
(
W1130-02-11
)
Comparison of a Microfluidic Generic Total Antibody (TAb) Assay with Independent Neutralizing Antibody (NAb) and TAb Assays for the Detection of Pre-existing Antibodies against AAV Vectors
Frida Löthberg
Favorite
Lachacz, Eric
AstraZeneca
(
T1130-02-06
)
Biodistribution Analysis of GPC-3 CAR-T Cells in NSG Mice by a Universal ddPCR Assay to Support an IND-Enabling Toxicity Study
Eric Lachacz
Favorite
Lakshminarasimhan, Maha
Merck Sharp & Dohme Corp.
(
W1330-02-07
)
Enhancing Antibody Detection for PABAD-Based Neutralizing Antibody Detection and Validation
Maha Lakshminarasimhan
Favorite
Lee, Shin-Jae
University of Southern California
(
W1230-01-03
)
Elastin-Like Polypeptide (ELP) Antibody Fusions Targeting IL-6: Pharmacology and Pharmacokinetics
Shin-Jae Lee
Favorite
Lee, Sun
Ultragenyx Pharmaceuticals
(
W1530-02-06
)
Age-Dependent Reduction in Hepatic Vector Genome Loss in Juvenile OTC
spf-ash
Mice Following a Single Dose of DTX301 and Partial Compensation Achieved with a Higher Dose
Sun Lee
Favorite
Lehmann, Michael
AstraZeneca
(
W1230-02-09
)
LC-MS FFPE Tissue Analysis Across Multiple Murine Tissues Supports Mouse Relevance for On-Target/Off-Tumor Toxicity Assessment for Anti-STEAP2 CAR-T Therapeutic Development
Michael Lehmann
Favorite
Lelias, Sandra
EpiVax, Inc.
(
W1130-02-09
)
Immunogenicity Risk Assessment of Salmon Calcitonin Peptide Impurities Using In Silico and In Vitro Methods
Sandra Lelias
Favorite
Li, Amy Hao
Genentech, Inc.
(
T1330-02-09
)
Gyrolab Generic Anti-drug Antibody Assay Streamlines Preclinical Immunogenicity Assessment
Amy Hao Li
Favorite
Liao, Karen
Merck & Co., Inc.
(
T1530-02-09
)
False Positive or Not? – Assessing Potential Interference of Soluble Target to ADA Detection for a Clinical Stage Program
Karen Liao
Favorite
Li, Fengxia
Ultragenyx Pharmaceuticals
(
W1530-02-06
)
Age-Dependent Reduction in Hepatic Vector Genome Loss in Juvenile OTC
spf-ash
Mice Following a Single Dose of DTX301 and Partial Compensation Achieved with a Higher Dose
Fengxia Li
Favorite
Li, Junyi
Genentech, Inc.
(
T1430-02-09
)
Bridging Bevacizumab PK from Adults to Pediatrics through PBPK Modeling
Junyi Li
Favorite
Lin, Alyse
Genentech, Inc.
(
T1230-02-09
)
Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Alyse Lin
Favorite
Linh, Dinh Khanh
University of Cincinnati
(
T1030-02-10
)
Synthesis a Cationic-Polymer Incorporating Carboxylesterase Active Ester for the Delivery of CRISPR/Cas9 to Ameliorate Hyperlipidemia
Dinh Khanh Linh
Favorite
(
W1030-01-03
)
Oral Delivery of Remdesivir Analogues: Alternatives for Intravenous Remdesivir with Reduced Potential Drug-Drug Interactions
Dinh Khanh Linh
Favorite
Lin, Zhongping
Frontage Laboratories, Inc.
(
W1530-02-11
)
Evaluation of API 7500 Integrated System with Microflow LC System M5 Using Sulfamethazine (SDX) Neat Solution
Zhongping Lin
Favorite
Lin, Yu-Jiun (Nate)
Merck & Co., Inc.
(
T1130-02-10
)
A Novel Approach to Mechanical Characterization of Pharmaceutical Lyospheres
Yu-Jiun (Nate) Lin
Favorite
Liu, Bob
Genentech, Inc.
(
T1330-02-06
)
Utilizing a Bead-Based Sample Pretreatment to Overcome Drug Interference in Developing a Ligand Binding Neutralizing Antibody Assay
Bob Liu
Favorite
Liu, Chang
Genentech, Inc.
(
T1330-02-07
)
Optimizing and Validating an In Vitro Transcytosis Assay for Predicting Pharmacokinetics in Drug Discovery and Process Development
Chang Liu
Favorite
(
T1430-01-03
)
Val-His-Ser (VHS) N-terminal Leader Sequence and Implications for mAb Subcutaneous Pharmacokinetics
Chang Liu
Favorite
Liu, Hui
AstraZeneca
(
T1130-02-06
)
Biodistribution Analysis of GPC-3 CAR-T Cells in NSG Mice by a Universal ddPCR Assay to Support an IND-Enabling Toxicity Study
Hui Liu
Favorite
Liu, Luna
Genentech, Inc.
(
T1430-01-03
)
Val-His-Ser (VHS) N-terminal Leader Sequence and Implications for mAb Subcutaneous Pharmacokinetics
Luna Liu
Favorite
(
T1530-02-08
)
Cross Validation of Pharmacokinetic Assays: Experimental and Statistical Design
Luna Liu
Favorite
Liu, Stephanie
Genentech, Inc.
(
T1230-02-09
)
Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Stephanie Liu
Favorite
Liu, Wei
Teva Pharmaceuticals, Inc.
(
W1230-01-02
)
Impact of Amino Acids as Excipients in Biologic Drug Products Formulation Development
Wei Liu
Favorite
Liu, Wenyu
Genentech, Inc.
(
T1330-02-06
)
Utilizing a Bead-Based Sample Pretreatment to Overcome Drug Interference in Developing a Ligand Binding Neutralizing Antibody Assay
Wenyu Liu
Favorite
Liu, Xiaoyan
Genentech, Inc.
(
T1230-02-09
)
Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Xiaoyan Liu
Favorite
Li, Yihan
Abbvie
(
T1430-02-10
)
A Novel In Vitro Serum Stability Assay for Antibody Therapeutics Incorporating Internal Standards
Yihan Li
Favorite
Lodaya, Rushit
GlaxoSmithKline plc
(
W1330-01-05
)
Extrapolating the Use of Microfluidic Chips to Formulate Reproducible and Effective Nanoemulsions for Subunit Vaccines: A Paradigm Shift in Manufacturing Emulsion Adjuvants
Rushit Lodaya
Favorite
Lowes, Steve
Q Squared Solutions
(
W1430-02-09
)
Exploring the Future Potentials of High-Resolution Mass Spectrometry for Regulated Bioanalysis
Steve Lowes
Favorite
Luo, Linlin
Merck & Co., Inc.
(
T1530-02-09
)
False Positive or Not? – Assessing Potential Interference of Soluble Target to ADA Detection for a Clinical Stage Program
Linlin Luo
Favorite
